диссертации / 42

91

66Krueger WA Bulitta J Kinzig-Schippers M et al. Evaluation of Monte Carlo simulation of the pharmacokinetics of two doses of meropenem administrated intermittently or as a continuous infusion in healthy volunteers. J Antimicrob Aents Chemother 2005; 49(5):1881-9

67Kuti JL, Dandekar PK, Nightingale CH. Use of Monte Carlo simulation to design an optimized pharmacodinamic dosing strategy for meropenem. J Clin Pharmacol 2003; 43; 1116-23

68Lomaestro BM, Drussano GL. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. J Antimicrob Agents Chemother 2005; 49 (1): 461-3

69Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. J Clin Ther. 2008 May;30(5):868-83.

70Masterton R.G. et al., Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy. J

Antimicrob Chemother, 2008

71 McGarry LJ, Merchant S, Nathwani D, Pawar V, Delong K, Thompson D, Akhras K, Ingham M, Weinstein MC. Economic assessment of doripenem versus imipenem in the treatment of ventilator-associated pneumonia. J Med Econ. 2010 Mar;13(1):142

72Merchant S, Gast C, Nathwani D, Lee M, Quintana A, Ketter N, Friedland I, Ingham M. Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia. J Clin Ther. 2008 Apr;30(4):717-33.

92

73Meyer E, Buttler J, Schneider C, Strehl E, Schroeren-Boersch B, Gastmeier P, Ruden H, Zentner J, Daschner FD, Schwab F. Modified guidelines impact on antibiotic use and costs: duration of treatment for pneumonia in a neurosurgical ICU is reduced. J Antimicrob Chemother. 2007 Jun; 59(6):1148-54.

74Michalopoulos A, Falagas ME. Treatment of Acinetobacter infections. Expert Opin Pharmacother. 2010 Apr;11(5):779-88

75Mouton YJ, Beuscart C; Meropenem Study Group. Empirical monotherapy with meropenem in serious bacterial infections. J Antimicrob Chemother 1995 ; 36 (Suppl A): 145 -56

76Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004 ; 48 (8): 3086 -92.

77Niederman M.S., Craven D.E. et al. American Thoracic Society and the Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator associated, and healthcareassociated pneumonia. Am J Respir Crit Care Med 2005 ; 171 : 388 -416

79Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. J Clin Microbiol Infect 2006 ; 12 (9): 826 -36

80Ramphal R, Ambrose PG. Extended-spectrum beta-lactamases and clinical outcomes: current data. J Clin Infect Dis. 2006 Apr 15;42 Suppl 4:S164-72

81Ramphal R. Importance of adequate initial antimicrobial therapy. J Chemotherapy. 2005 Jul;51(4):171-6

93

82Raritan NJ. Doribax [package insert]. Ortho-NcNeil Pharmaceutical Inc; 2007

83Rea-Neto A, Niederman M, Lobo SM, et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. J Curr Med Res Opin. 2008;24(7):2113–2126.

84Redman R, File TM. Safety of intravenous infusion of doripenem. J. Clin Infect Dis. 2009 Aug 15;49 Suppl 1:S28-35

85Rhomberg PR, Jones RN, Sader HS; Mystic Programme (US) Study Group. Results from the Meropenem YearlySusceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United Statesmedical centres. Int J Antimicrob Agents 2004 ; 23 : 52 -9

86Rhomberga P.R., Ronald N. Jonesab Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999–2008). J Diagn Microbiol and Infect Disease. Vol.65, Issue4, p.414-426

87Sakyo S, Tomita H, Tanimoto K, et al. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem. J Antibiot 2006 ; 59 (4): 220 -8

88Santos SS, Machado FR, Kiffer CR, Barone AA. Treatment of nosocomial pneumonia: an experience with meropenem. Braz J Infect Dis2001 ; 5 (3): 124 -9

89Schmitt DV, Leitner E, Welte T, Lode H. Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia--a double blind prospective multicentre study. J Infection 2006 Jun;34(3):127-34.

94

90Shore KP, Roberts SA, Paviour SD, et al. Antimicrobial susceptibility of anaerobic bacteria in New Zealand: 1999-2003.J Antimicrob Chemother 2006 May; 57 (5): 992-8

91Seiger B, Berman SJ, Geckler R, Farkas S. Empiric treatment of hospitalacquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Crit Care Med 1997 ; 25 (10): 1663 -70

92Solomkin J., Umeh O., Jiang J., Doripenem versus Imipenem for the treatment of complicated intraabdominal infections. In programm and abstracts of the 47thICAAC; American society for microbiology.

93Sumita Y, Fukasawa M, Okuda T. Affi nities of SM-7338 for penicillin binding protein and its release from these proteins in Staphylococcus aureus. J Antimicrob Agents Chemother 1990 ; 34 (3): 484 -6

94Sumita Y, Fuksawa M, Okuda T. Comparison of two carbapenems, SM7338 and imipenem: affinities for penicillin binding protein and morphological changes. J Antibiot (Tokyo) 1990 ; 43 (3): 314 -20

95Sun HK, Kuti JL, Nicolau DP. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program. Crit Care Med. 2005 Oct;33(10):2222-7

96Torres A, Bauer TT, Leon-Gill C, et al. Treatment of severe nosocomial pneumonia: a prospective randomized comparison of intravenous ciprofloxacin with imipenem/cilastatin. J. Thorax 2000 ; 55 : 1033 -9

aeruginosa strains in patients with ventilator-associated pneumonia in intensive care units. Medicina (Kaunas). 2011;47(12):652-6.

98West M, Boulanger B, Fogarty C, et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-

95

label study. J Clin Ther 2003 ; 23 (2): 485 -505

99Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenem–cilastatin for treatment of nosocomial pneumonia in intensive care unit patients; a multicenter, evaluator-blind, prospective, randomized study. J Antimicrob Agents Chemother 2003 ; 47 (11): 3442 -7

100Zhanel G.G., Simor A.E., Vercagine L. et al. Imipenem and Meropenem comparision of in vitro activity, pharmacokinetics, clinical trials and adverse effects. Can J Inf Dis 1998; 9: 215-28.

101Zhanel GG, Ketter N, Rubinstein E, Friedland I, Redman R. Overview of seizure-inducing potential of doripenem. J Drug Saf. 2009;32(9):709-16.

102Zilberberg MD, Mody SH, Chen J, Shorr AF. Cost-effectiveness model of empiric doripenem compared with imipenem-cilastatin in ventilatorassociatedpneumonia. J Surg Infect (Larchmt). 2010 Oct;11(5):409-17.